Newco Ziarco debuts to develop Pfizer programs

Newco Ziarco Pharma Ltd. (Canterbury, U.K.) debuted on Monday with $6 million in a series A round and exclusive, worldwide rights to develop and commercialize a portfolio of four assets from Pfizer Inc. (NYSE:PFE) for inflammatory and allergic diseases. The $6 million is the first tranche of a planned $27 million series A round led by Biotechnology Value Fund. Pfizer Venture Investments participated. Pfizer will receive an undisclosed equity stake in Ziarco and is eligible for undisclosed milestones, plus royalties. ...